Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

OMNIPAQUE INJECTION 350 MG I/ML [SIN05923P]

Active ingredients: OMNIPAQUE INJECTION 350 MG I/ML

View product's general information
Last updated 24 April 2026

Product Info

OMNIPAQUE INJECTION 350 MG I/ML

[SIN05923P]

Product information

Active Ingredient and Strength

IOHEXOL 755 MG/ML EQV IODINE - 350 MG/ML

Dosage Form

INJECTION

Manufacturer and Country

GE HEALTHCARE IRELAND LIMITED (BY PARAMETRIC RELEASE) - IRELAND
GE HEALTHCARE AS (BY PARAMETRIC RELEASE) - NORWAY
GE HEALTHCARE (SHANGHAI) CO., LTD - CHINA

Registration Number

SIN05923P

Licence Holder

GE HEALTHCARE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V08AB02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 THERAPEUTIC INDICATIONS

This medicinal product is for diagnostic use only.
X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT-enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract.

Dosing

4.2 POSOLOGY AND METHOD OF ADMINISTRATION

The dosage varies depending on the type of examination, age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume is used as with other iodinated X-ray contrast media in current use. Adequate hydration should be assured before and after administration as for other contrast media.
For intravenous, intra-arterial and intrathecal use, and use in body cavities.
The following dosages may serve as a guide.

Guidelines for intravenous use

Omnipaque Dosage Table 1



Guidelines for intra-arterial use

Omnipaque Dosage Table 2



Guidelines for intrathecal use

Omnipaque Dosage Table 3



To minimize possible adverse reactions a total dose of 3 g iodine should not be exceeded.

Guidelines for Body cavities

Omnipaque Dosage Table 4



Contraindications

4.3 CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients (See Section 6.1 LIST OF EXCIPIENTS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Manifest thyrotoxicosis.